Lyell Immunopharma Inc
LYEL
Lyell Immunopharma Inc AI Insights
Informational only. Not investment advice.Snapshot
- Cash burn of -165M FCF TTM against 124M cash leaves ~9 months runway without financing[Free Cash Flow TTM]
- R&D spend of 155M TTM is 3,785x revenue (41K) - pure clinical-stage bet with no commercial traction[Research and Development TTM]
- Trading at 1.6x book (329M equity) but book is 100% tangible - no goodwill impairment risk[P/B Ratio]
Watch Triggers
- Cash and Equivalents: Falls below 80M or rises via financing — Sub-80M triggers survival mode; equity raise signals dilution magnitude
- Research and Development TTM: Drops >20% sequentially — R&D cut signals pipeline prioritization or distressed cost-cutting
- Total Revenue TTM: Exceeds 5M — Would indicate meaningful licensing deal or partnership milestone
Bull Case
Clean balance sheet with 0.13 debt/equity and 329M tangible book provides acquisition floor; no goodwill writedown risk
3Y revenue growth of 71% (albeit from near-zero base) signals early partnership/licensing traction
Bear Case
9-month cash runway at current burn forces near-term dilution or asset sale; no path to profitability visible
ROE of -76% and ROA of -63% TTM rank among worst in biotech; capital destruction accelerating
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage LYEL's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Dilutive financing likely within 12 months as cash runway insufficient for clinical milestones
- 124M cash vs 165M annual burn rate
- No meaningful revenue to offset OpEx
- Clinical trials require sustained investment
Public Strategies Rankings
See how Lyell Immunopharma Inc ranks across different investment strategies.
Leverage LYEL's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
LYEL Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$596.27M | — | ||
$516.98M | — | ||
0.00 | — | ||
$41,000 | -34.9% | — | |
$-13.70 | — | ||
-495,080% | -150451.9% | — | |
-794,293% | -470500.6% | — | |
$-165.53M | — | ||
-0.76 | -42.5% | — | |
Beta 5Y (Monthly) | unknown | — |
LYEL Dividend History
LYEL Stock Splits
LYEL SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
11/12/25 | 09/30/25 | 10-Q | |
08/12/25 | 06/30/25 | 10-Q | |
05/13/25 | 03/31/25 | 10-Q | |
03/11/25 | 12/31/24 | Unknown | |
11/07/24 | 09/30/24 | 10-Q | |
08/07/24 | 06/30/24 | 10-Q | |
05/06/24 | 03/31/24 | 10-Q | |
02/28/24 | 12/31/23 | 10-K | |
11/07/23 | 09/30/23 | 10-Q | |
08/08/23 | 06/30/23 | 10-Q | |
05/04/23 | 03/31/23 | 10-Q | |
02/28/23 | 12/31/22 | 10-K | |
11/08/22 | 09/30/22 | 10-Q | |
08/04/22 | 06/30/22 | 10-Q | |
05/10/22 | 03/31/22 | 10-Q | |
03/29/22 | 12/31/21 | 10-K | |
11/12/21 | 09/30/21 | 10-Q | |
08/12/21 | 06/30/21 | 10-Q | |
06/18/21 | 03/31/21 | 424B4 | |
06/18/21 | 12/31/20 | 424B4 | |
11/12/21 | 09/30/20 | 10-Q | |
08/12/21 | 06/30/20 | 10-Q | |
06/18/21 | 03/31/20 | 424B4 |